6:43 PM
Apr 02, 2007
 |  BC Extra  |  Company News

NICE recommends against Tysabri, Alimta, MabThera

Appraisal committees for the National Institute for Health and Clinical Excellence issued recommendations against the use of three drugs on the U.K.'s National Health System: Tysabri natalizumab from Biogen...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >